Teleflex has announced its ArrowADVANTAGE5 pressure-injectable peripherally inserted central catheter has received FDA clearance for central venous pressure monitoring indication, according to a news release.
The non-coated PICC is designed for clinician ease-of-use, smooth insertion and patient comfort, according to the company.
"With the ArrowADVANTAGE5, we offer the next generation of non-coated pressure-injectable PICCs," said Paul Molloy, president, vascular division of Teleflex, in the release. "Beyond the unique advantages of our PICC, we are pleased to add the CVP monitoring indication. Additionally, the distal lumen is compatible with the ARROW VPS System1, enabling clinicians to combine the advantages of our PICC with state-of-the-art tip location technology."
Teleflex is headquartered in Limerick, Pa.
Related Articles on FDA Clearances:
Abbott Receives FDA Clearance for Cataract Surgery Protective Gel
ProPep Surgical Receives FDA Clearance for Nerve Monitoring System
Ultrasonix Medical Receives FDA Approval for Needle Guidance Technology